Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NVAX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Novavax COVID-19 Vaccine | COVID-19 | Phase 4 · NCT06065176 | Completed |
| Pfizer COVID-19 mRNA vaccine (2023-2024 | COVID-19 | Phase 4 · NCT06065176 | Completed |
| Pfizer mRNA COVID-19 vaccine | COVID-19 | Phase 4 · NCT06633835 | Completed |
| protein subunit: Novavax COVID-19 vaccin | COVID-19 | Phase 4 · NCT06633835 | Completed |
| Aluminum Hydroxide Adjuvanted Inactivate | Severe Acute Respiratory Syndrome Coronavirus 2 (S | Phase 3 · NCT05249816 | Completed |
| Bivalent BA.4/5 | COVID-19 | Phase 2/3 · NCT05925127 | Completed |
| CIC Vaccine Co-formulated tNIV2 , SARSCo | COVID-19 | Phase 3 · NCT06291857 | Completed |
| coformulated CIC Vaccine | COVID-19 | Phase 2/3 · NCT06482359 | Withdrawn |
| Fluzone HD trivalent | COVID-19 | Phase 2/3 · NCT06482359 | Withdrawn |
| Trivalent Influenza Vaccine | COVID-19 | Phase 3 · NCT06291857 | Completed |
| Quadrivalent Inactivated Influenza Vacci | Influenza, Human | Phase 3 · NCT04120194 | Completed |
| Formulation buffer | Respiratory Syncytial Virus Infections | Phase 3 · NCT02624947 | Completed |
| Licensed seasonal influenza vaccine | SARS-CoV-2 Infection | Phase 3 · NCT04583995 | Completed |
| NanoFlu | Influenza, Human | Phase 3 · NCT04120194 | Completed |
| SARS-CoV-2 rS Nanoparticle Vaccine NVX-C | COVID-19 | Phase 3 · NCT05463068 | Completed |
| NVX-CoV2515 | COVID-19 | Phase 3 · NCT05372588 | Completed |
Also used in these trials (approved or third-party drugs, not NVAX's own candidates): Saponin-based Adjuvant, Adjuvant, SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Adjuvant 1, Matrix-M Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NVAX holds $719.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $52.6M/quarter from operations, an estimated runway of 41 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVAX files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVAX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →